Drug intelligence / Profile preview

VIR-2703

Development stage: Discontinued
Lead developer: Vir Biotechnology
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Inhalation

Overview

VIR-2703, also known as ALN-COV, is an **inhaled formulation of small interfering RNA (siRNA)** developed by Vir Biotechnology and Alnylam Pharmaceuticals. It is designed to target the SARS-CoV-2 genome for the treatment or prevention of COVID-19. VIR-2703 has shown significant potency in reducing viral replication in vitro, with an EC50 of less than 100 picomolar and an EC95 of less than 1 nanomolar[1][3][5].

Other names: VIR-2703VIR2703VIR 2703ALN-COV

Targets

SARS-CoV-2 RNA

Beyond the preview

Go deeper on VIR-2703.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIR-2703.

Explore the full profile